It is trading at $4.45 a tad higher than the 50 day moving average which is $4.09 and slightly over the 200 day moving average of $4.11. The 50 day moving average moved up $0.36 and the 200 day average moved up $0.34. 334K shares changed hands on Wednesday. Overall, volume was up 90.62% over the stocks normal daily volume.
Traders are more bearish on shares of T2 Biosystems, Inc. of late if you watch the change in short interest. The stock realized a rise in short interest between August 15, 2017 and August 31, 2017 of 4.74%. Short interest increased from 1,363,689 to 1,428,346 over that timeframe. With short interest at 1,428,346 and short average daily volume at 111,965, the short-interest ratio is 13.0 and the percentage of shorted shares is 0.05% as of August 31.
These funds have shifted positions in (TTOO). Lagoda Investment Management, L.p. grew its stake by buying 264,337 shares an increase of 15.4%. Lagoda Investment Management, L.p. now controls 1,975,921 shares valued at $6,343,000. The value of the position overall is down by 29.5%. As of the end of the quarter Ubs Group Ag had sold 558 shares trimming its stake by 77.9%. The value of the investment in (TTOO) decreased from $4,000 to $1,000 a change of $3,000 since the last quarter.
As of quarter end Aisling Capital LLC had disposed of a total of 1,307,493 shares trimming its position 46.2%. The value of the investment in TTOO went from $14,891,000 to $4,890,000 a change of 67.2% for the reporting period. Tower Research Capital LLC (trc) augmented its ownership by buying 3,908 shares an increase of 1,608.2% as of 06/30/2017. Tower Research Capital LLC (trc) owns 4,151 shares with a value of $13,000. The total value of its holdings increased 1,200.0%.
In the last earnings report the EPS was $-1.97 and is estimated to be $-1.93 for the current year with 30,764,000 shares outstanding. Next quarter’s EPS is estimated at $-0.46 and the next full year EPS is anticipated to be $-1.53.
T2 Biosystems, Inc., launched on April 27, 2006, is an in vitro diagnostics company that is involved in developing a technology platform offering an alternative to diagnostic methodologies. The Company is focused on developing and launching commercially its diagnostic products aimed at reducing mortality rates, improving patient outcomes and reducing the cost of healthcare. The Business’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Business’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements..